CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Results of operations · Regulation FD disclosure
- 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 145 shares (to pay taxes)
- 4 Shares withheld for taxes CEO and President gave up 150 shares (to pay taxes)
- 8-K Event Regulation FD disclosure
- 4 Derivatives Options or other derivatives
- EFFECT Other Notice of Effectiveness
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- UPLOAD Other SEC-generated Letter
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-3 Offering Registration Statement
- SC 13G Stake Amended Statement of Ownership
- 4 Shares withheld for taxes CEO and President gave up 6,676 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 6,460 shares (to pay taxes)
- 4 Open-market buy SVP-Chief Operating Officer bought 2,000 shares at $3.99 ($7,980)
- 4 Open-market buy Director bought 22,971 shares at an average $3.79 ($86,977)
- 4 Open-market buy CEO and President bought 8,000 shares at an average $3.87 ($30,987)
- 4 Open-market buy SVP-HR and Org. Development bought 1,000 shares at $3.99 ($3,990)
Page 28 of 35 · 690 filings